Quick Answer
Vera Therapeutics, Inc. reported Stockholders Equity of $604.52 million for fiscal year 2025.
Vera Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $604.52M | +4.7% |
| 2024 | $577.15M | +467.6% |
| 2023 | $101.69M | +32.2% |
| 2022 | $76.91M | +10.5% |
| 2021 | $69.59M | +177.9% |
| 2020 | -$89.35M | -144.5% |
| 2019 | -$36.55M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $398.88M | +38.0% | -14.8% |
| June 30, 2025 | $468.28M | +42.8% | -12.5% |
| March 31, 2025 | $535.00M | +51.3% | -7.3% |
| December 31, 2024 | $577.15M | +467.6% | +99.7% |
| September 30, 2024 | $289.06M | +133.7% | -11.8% |
| June 30, 2024 | $327.87M | +133.3% | -7.3% |
| March 31, 2024 | $353.54M | +124.2% | +247.7% |
| December 31, 2023 | $101.69M | +32.2% | -17.8% |
- Vera Therapeutics, Inc. showed an increase of +4.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Vera Therapeutics, Inc.’s stockholders equity has grown by 1754.0% (from -$36.55 million to $604.52 million).
- The most recent figure is from Vera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: